Tenecteplase Versus Alteplase Before Endovascular Therapy for Ischemic Stroke
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 202 participants.
Also called NCT02388061
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 202 participants
- Registry
-
NCT02388061
-
- Other papers using this trial's data
- Tenecteplase versus Alteplase before Thrombectomy for Ischemic Stroke
- Tenecteplase versus alteplase before endovascular thrombectomy (EXTEND-IA TNK): A multicenter, randomized, controlled study
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Australia, New Zealand
- Registry status
- Completed
Technical summary
Registry record NCT02388061. Randomized; no masking; primary purpose treatment. Start 2015-03-23 (actual); primary completion 2017-10-16 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Tenecteplase Versus Alteplase Before Endovascular Therapy for Ischemic Stroke
- Acronym
- EXTEND-IA TNK
- Condition
- Ischemic Stroke
- Intervention (Drug)
- Tenecteplase
- Intervention (Drug)
- Tissue Plasminogen Activator
- Lead sponsor
- Neuroscience Trials Australia
- Collaborator
- The Florey Institute of Neuroscience and Mental Health
Record details
- Record id
cardio:ct-nct02388061- Content hash
f6acee7b1e0e141add12ee174f5c33b59026bf2604bc2d27a7168678b7c3047f